Wegovy
MarketedA once-weekly obesity injection approved by Korea's MFDS in April 2023 and launched in Korea in October 2024; it ranked first in Korean prescription-drug sales in Q2 2025.
FROM PUBLIC EVENTS · 2026-11-18
Commercial · sales Supplies Wegovy in Korea, co-promotes it with Chong Kun Dang and has started Korean Phase 3 trials of a next-generation obesity drug.
Roles often seen at this stageSales & marketing · Medical & MSL · Clinical & PV
The Korean arm of Denmark's Novo Nordisk, supplying medicines such as the obesity drug Wegovy in Korea and running Korean clinical trials.
A once-weekly obesity injection approved by Korea's MFDS in April 2023 and launched in Korea in October 2024; it ranked first in Korean prescription-drug sales in Q2 2025.
Next-generation obesity candidate; in February 2026 the MFDS approved two Phase 3 trials (AMAZE 2 and HF-POLARIS) that include Korean patients.
Two amycretin Phase 3 trials were approved by the MFDS, with 215 Korean patients taking part.
Signed a Korean co-promotion agreement for Wegovy with Chong Kun Dang, with joint sales to hospitals and clinics from October 2025.
Introduced tiered pricing for Wegovy in Korea, lowering prices by up to 40% depending on dose.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.